Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MW5431
- Development stage
- Unknown
- Lead developer
- Shanghai Minwei Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
MW5431 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Shanghai Minwei Biotechnology for the treatment of metabolic disorders, including type 2 diabetes mellitus and obesity. It is a recombinant peptide designed to mimic the action of the endogenous incretin hormone GLP-1, which regulates blood glucose levels by stimulating insulin secretion and inhibiting glucagon release in a glucose-dependent manner. Additionally, MW5431 acts on the central nervous system to increase satiety and slow gastric emptying, facilitating weight loss. The drug is currently undergoing Phase 1 clinical evaluation in China to assess its safety, tolerability, and pharmacokinetic profile in both diabetic and overweight/obese populations.
Beyond the preview
Go deeper on MW5431.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MW5431.